T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 298, Issue 4, 2010, Pages

  De Miguel, Carmen ^a   Das, Satarupa ^a   Lund, Hayley ^a   Mattson, David L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Blood pressure; Rats; Sodium dependent hypertension

Indexed keywords

ALBUMIN; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RENIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; ENZYME ACTIVITY; GLOMERULUS FILTRATION RATE; HYPERTENSION; IMMUNOCOMPETENT CELL; KIDNEY; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY PARENCHYMA; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SALT INTAKE; T LYMPHOCYTE; TUBULAR DYSFUNCTION; URINARY EXCRETION;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; HYPERTENSION; KIDNEY; KIDNEY GLOMERULUS; KIDNEY TUBULES; MALE; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED DAHL; RENIN; SERUM ALBUMIN; T-LYMPHOCYTES;

EID: 77949868470     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00298.2009     Document Type: Article

References (48)

1. Alvarez V, Quiroz Y, Nava M, Pons H, Rodríguez-Iturbe B. Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 283: F1132-F1141, 2002.
2. Bataillard A, Vincent M, Sassard J, Tourain JL. Antihypertensive effect of cyclophosphamide in genetically hypertensive rats. Int J Immunopharmacol 11: 377-384, 1989.
3. Bendich A, Belisle EH, Strausser HR. Immune system modulation and its effect on the blood pressure of the spontaneously hypertensive male and female rat. Biochem Biophys Res Commun 99: 600-607, 1981.
4. Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol 293: F616-F623, 2007.
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
6. Cholewa BC, Meister CJ, Mattson DL. Importance of the renin-angiotensin system in the regulation of arterial blood pressure in conscious mice and rats. Acta Physiol Scand 183: 309-320, 2005.
7. Dzielak DJ. The immune system and hypertension. Hypertension 19: 36-44, 1992.
8. Franco M, Martinez F, Quiroz Y, Galicia O, Bautista R, Johnson RJ, and Rodriguez-Iturbe B. Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 293: R251-R256, 2007.
9. Fu MLX. Do immune system changes have a role in hypertension? J Hypertens 13: 1259-1265, 1995.
10. Fukuda N, Nakayama M, Jian T, Satoh C, Nakayama T, Soma M, Izumi Y, Kanmatsuse K. Leukocyte angiotensin II levels in patients with essential hypertension: relation to insulin resistance. Am J Hypertens 16: 129-134, 2003.
11. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460, 2007.
12. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 96: 2407-2413, 1997.
13. Huang BS, Leenen FHH. Both brain angiotensin II and "ouabain" contribute to sympathoexcitation and hypertension in Dahl S rats on high salt intake. Hypertension 32: 1028-1033, 1998.
14. Jankowski V, Vanholder R, van der Giet M, Henning L, Tolle M, Schonfelder G, Krakow A, Karadogan S, Gustavsson N, Gobom J, Webb J, Lehrach H, Giebing G, Schluter H, Hilgers KF, Zidek W, Jankowski J. Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension 46: 591-597, 2005.
15. Johnson RJ, Rodriguez-Iturbe B, Nakagawa T, Kang DH, Feig DI, Herrera-Acosta J. Subtle renal injury is a likely common mechanism for salt-sensitive essential hypertension. Hypertension 45: 326, 2005.
16. Johnson RJ, Herrera-Acosta J, Schreiner GF, and Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346: 913-923, 2002.
17. Khraibi AA, Smith TL, Hutchins PM, Lynch CD, Dusseau JW. Thymectomy delays the development of hypertension in Okamoto spontaneously hypertensive rats. J Hypertens 5: 537-541, 1987.
18. Khraibi AA. Association between disturbances in the immune system and hypertension. Am J Hypertens 4: 635-635, 1991.
19. Kitazano T, Padgett RC, Armstrong ML, Tompkins PK, Heistad DD. Evidence that angiotensin II is present in human monocytes. Circulation 91: 1129-1134, 1995.
20. Kobori H, Ozawa Y, Suzaki Y, Prieto-Carrasquero MC, Nishiyama A, Shoji T, Cohen EP, Navar LG. Young scholars award lecture: Intratubular angiotensinogen in hypertension and kidney diseases. Am J Hypertens 19: 541-550, 2006.
21. Kodama K, Adachi H, Sonoda J. Beneficial effects of long-term enalapril treatment and low-salt intake on survival rate of Dahl salt-sensitive rats with established hypertension. J Pharmacol Exp Ther 283: 625-629, 1997.
22. Leenen FHH, Yuan B. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Hypertension 37: 981-984, 2001.
23. Lombardi D, Gordon K, Polinksy P, Suga S, Schwartz S, Johnson R. Salt sensitive hypertension develops after short-term exposure to angiotensin II. Hypertension 33: 1013-1019, 1999.
24. Mai M, Geiger H, Hilgens KF, Veelken R, Mann JFE, Daemmrich J, Luft FC. Early changes in hypertension induced renal injury. Hypertension 22: 754-765, 1993.
25. Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 48:149 -156, 2006.
26. Mattson DL, Kunert MP, Kaldunski ML, Greene AS, Roman RJ, Jacob HJ, Cowley AW Jr. Influence of diet and genetics on hypertension and renal disease in Dahl salt-sensitive rats. Physiol Genomics 16: 194-203, 2004.
27. Mattson DL, Wu F. Nitric oxide synthase activity and isoforms in the rat renal vasculature. Hypertension 35: 337-341, 2000.
28. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 161: 1679-1693, 2002.
29. Nahmod KA, Vermeulen ME, Radien S, Salamone G, Gamberale R, Fernandez-Calotti P, Alvarez A, Nahmod V, Giordana M, Geffner JR. Control of dendritic cell differentiation by angiotensin II. FASEB J 17: 491-493, 2003.
30. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 39: 316-322, 2002.
31. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 39: 129-134, 2002.
32. Otsuka F, Yamauchi T, Kataoka H, Mimura Y, Ogura T, Makino H. Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 274: R1797-R1806, 1998.
33. Ozawa Y, Kobori H, Suzaki Y, Navar LG. Sustained renal interstitial macrophage infiltration following chronic Angiotensin II infusions. Am J Physiol Renal Physiol 292: F330-F339, 2007.
34. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
35. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 98: 800-807, 1998.
36. Quiroz Y, Pons H, Gordon KL, Rincón J, Chávez M, Parra G, Herrera-Acosta J, Gómez-Garre D, Larfo R, Egido J, Johnson RJ, Rodríguez-Iturbe B. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthase inhibition. Am J Physiol Renal Physiol 281: F38-F47, 2001.
37. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26: 137-143, 1984.
38. Rieder MJ, Roman RJ, Greene AS. Reversal of microvascular rarefaction and reduced renal mass hypertension. Hypertension 30: 120-127, 1997.
39. Rodriguez-Iturbe B, Vaziri ND, Herrera Acosta J, and Johnson RJ. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286: F606-F616, 2004.
40. Rodriguez-Iturbe B, Johnson RJ. The role of inflammatory cells in the kidney in the induction and maintenance of hypertension. Nephrol Dial Transplant 21: 260-263, 2006.
41. Rodríguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincón J, Chávez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59: 2222-2232, 2001.
42. Rodríguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chávez M, Herrera-Acosta J, Johnson RJ, Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282: F191-F201, 2002.
43. Santos RA, Krieger EM, Greene LJ. An improved fluorometric assay of rat serum and plasma converting enzyme. Hypertension 7: 244-252, 1985.
44. Sealey JE, Laragh JH. How to do a plasma renin assay. Cardiovasc Med 2: 1079-1092, 1977.
45. Stewart T, Jung FF, Manning J, Vehaskari VM. Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. Kidney Int 68: 2180-2188, 2005.
46. Svendsen UG. Evidence for an initial, thymus independent, and a chronic, thymus-dependent phase of DOCA and salt hypertension in mice. Path Microbiol Scand Acta 84: 523-528, 1976.
47. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67: 799-812, 2005.
48. Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, Suzuki K, Higaki J, Ogihara T. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 33: 335-339, 1999.